Clinical Trial Update: Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of oral azacitidine (CC-486) versus investigator's choice therapy in relapsed or refractory angioimmunoblastic T-ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma

Drugs mentioned

• CC-486 (oral azacitidine) (azacitidine)

Snippet

Sponsor: Celgene | Conditions: Lymphoma, T-Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-07-08